{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:50:16Z","timestamp":1791316216936,"version":"4.3.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["LQ22H160008"],"award-info":[{"award-number":["LQ22H160008"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017594","name":"Medical Science and Technology Project of Zhejiang Province","doi-asserted-by":"publisher","award":["2025HY1004"],"award-info":[{"award-number":["2025HY1004"]}],"id":[{"id":"10.13039\/501100017594","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017594","name":"Medical Science and Technology Project of Zhejiang Province","doi-asserted-by":"publisher","award":["2024KY1550"],"award-info":[{"award-number":["2024KY1550"]}],"id":[{"id":"10.13039\/501100017594","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017594","name":"Medical Science and Technology Project of Zhejiang Province","doi-asserted-by":"publisher","award":["2025HY1005"],"award-info":[{"award-number":["2025HY1005"]}],"id":[{"id":"10.13039\/501100017594","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biomed"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Triple-negative breast cancer (TNBC) remains an aggressive disease with limited treatment options. Oncolytic adenoviruses represent a promising platform, but their efficacy as single agents is often insufficient. This study examined whether an oncolytic adenovirus\u00a0co-delivering decorin (DCN) and CD40 ligand (CD40L), designated rAd.DCN.CD40L, could enhance antitumor activity and immune activation against TNBC. Recombinant adenoviruses expressing DCN (rAd.DCN), CD40L (rAd.CD40L), or both proteins were constructed and evaluated in breast cancer cells using cell viability, apoptosis, migration, invasion, and damage-associated molecular pattern (DAMP) release assays. Compared with rAd.DCN or rAd.CD40L alone, rAd.DCN.CD40L triggered greater apoptosis and tumor cell death and elicited more pronounced DAMP release. Co-culture experiments also revealed enhanced dendritic cell function following rAd.DCN.CD40L treatment. For in vivo evaluation, syngeneic 4T1 and EMT-6 subcutaneous tumor models and a 4T1 lung metastasis model were employed. rAd.DCN.CD40L substantially delayed tumor growth and improved survival in tumor-bearing mice. Flow cytometric and histological analyses further confirmed enhanced local and systemic T-cell responses, elevated CD8\u207a T-cell activity, and modulated inflammatory macrophage phenotypes. Mechanistically, western blot analysis showed that rAd.DCN.CD40L may contribute to extracellular matrix remodeling and the down-regulation of the expression of epithelial-mesenchymal transition (EMT)-associated genes. Notably, CD8\u207a T-cell depletion markedly attenuated the therapeutic efficacy of rAd.DCN.CD40L, demonstrating that CD8\u207a T cells are critical functional effectors of tumor control. Collectively, these findings indicate that a DCN-\u00a0and CD40L-armed oncolytic adenovirus represents a promising combinatorial strategy for TNBC immunotherapy, and warrants further preclinical and clinical investigation.<\/jats:p>","DOI":"10.1186\/s43556-026-00570-w","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T02:41:32Z","timestamp":1791168092000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Oncolytic virus encoding decorin and the CD40 ligand boosts T-cell response and achieves a durable antitumor response during breast cancer treatment"],"prefix":"10.1186","volume":"7","author":[{"given":"Yingjun","family":"Ning","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yejing","family":"Rong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haifeng","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yudong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanqian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaoyun","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sijia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongshan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6537-2102","authenticated-orcid":false,"given":"Yuefeng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,5]]},"reference":[{"issue":"1","key":"570_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-022-00386-1","volume":"8","author":"P Tarantino","year":"2022","unstructured":"Tarantino P, Corti C, Schmid P, Cortes J, Mittendorf EA, Rugo H, et al. Immunotherapy for early triple negative breast cancer: research agenda for the next decade. NPJ Breast Cancer. 2022;8(1):23. https:\/\/doi.org\/10.1038\/s41523-022-00386-1.","journal-title":"NPJ Breast Cancer"},{"issue":"6573","key":"570_CR2","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1126\/science.abk3436","volume":"374","author":"A Melcher","year":"2021","unstructured":"Melcher A, Harrington K, Vile R. Oncolytic virotherapy as immunotherapy. Science. 2021;374(6573):1325\u20136. https:\/\/doi.org\/10.1126\/science.abk3436.","journal-title":"Science"},{"issue":"1","key":"570_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15010321","volume":"15","author":"L Li","year":"2023","unstructured":"Li L, Zhang F, Liu Z, Fan Z. Immunotherapy for triple-negative breast cancer: combination strategies to improve outcome. Cancers (Basel). 2023;15(1):321. https:\/\/doi.org\/10.3390\/cancers15010321.","journal-title":"Cancers (Basel)"},{"issue":"3","key":"570_CR4","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/s41571-022-00719-w","volume":"20","author":"SZ Shalhout","year":"2023","unstructured":"Shalhout SZ, Miller DM, Emerick KS, Kaufman HL. Therapy with oncolytic viruses: progress and challenges. Nat Rev Clin Oncol. 2023;20(3):160\u201377. https:\/\/doi.org\/10.1038\/s41571-022-00719-w.","journal-title":"Nat Rev Clin Oncol"},{"issue":"7","key":"570_CR5","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/s41568-018-0009-4","volume":"18","author":"K Twumasi-Boateng","year":"2018","unstructured":"Twumasi-Boateng K, Pettigrew JL, Kwok YYE, Bell JC, Nelson BH. Oncolytic viruses as engineering platforms for combination immunotherapy. Nat Rev Cancer. 2018;18(7):419\u201332. https:\/\/doi.org\/10.1038\/s41568-018-0009-4.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"570_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-00951-x","volume":"7","author":"Y Tian","year":"2022","unstructured":"Tian Y, Xie D, Yang L. Engineering strategies to enhance oncolytic viruses in cancer immunotherapy. Signal Transduct Target Ther. 2022;7(1):117. https:\/\/doi.org\/10.1038\/s41392-022-00951-x.","journal-title":"Signal Transduct Target Ther"},{"key":"570_CR7","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.coviro.2016.07.007","volume":"21","author":"D Saha","year":"2016","unstructured":"Saha D, Wakimoto H, Rabkin SD. Oncolytic herpes simplex virus interactions with the host immune system. Curr Opin Virol. 2016;21:26\u201334. https:\/\/doi.org\/10.1016\/j.coviro.2016.07.007.","journal-title":"Curr Opin Virol"},{"issue":"13","key":"570_CR8","doi-asserted-by":"publisher","first-page":"4374","DOI":"10.1158\/1078-0432.Ccr-09-0334","volume":"15","author":"RJ Prestwich","year":"2009","unstructured":"Prestwich RJ, Ilett EJ, Errington F, Diaz RM, Steele LP, Kottke T, et al. Immune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replication. Clin Cancer Res. 2009;15(13):4374\u201381. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-09-0334.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"570_CR9","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.4161\/cbt.7.8.6216","volume":"7","author":"F Benencia","year":"2008","unstructured":"Benencia F, Courr\u00e8ges MC, Fraser NW, Coukos G. Herpes virus oncolytic therapy reverses tumor immune dysfunction and facilitates tumor antigen presentation. Cancer Biol Ther. 2008;7(8):1194\u2013205. https:\/\/doi.org\/10.4161\/cbt.7.8.6216.","journal-title":"Cancer Biol Ther"},{"issue":"34","key":"570_CR10","doi-asserted-by":"publisher","first-page":"5763","DOI":"10.1200\/jco.2009.24.3675","volume":"27","author":"NN Senzer","year":"2009","unstructured":"Senzer NN, Kaufman HL, Amatruda T, Nemunaitis M, Reid T, Daniels G, et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol. 2009;27(34):5763\u201371. https:\/\/doi.org\/10.1200\/jco.2009.24.3675.","journal-title":"J Clin Oncol"},{"issue":"19","key":"570_CR11","doi-asserted-by":"publisher","first-page":"5859","DOI":"10.1158\/1078-0432.Ccr-06-0935","volume":"12","author":"YS Lee","year":"2006","unstructured":"Lee YS, Kim JH, Choi KJ, Choi IK, Kim H, Cho S, et al. Enhanced antitumor effect of oncolytic adenovirus expressing interleukin-12 and B7-1 in an immunocompetent murine model. Clin Cancer Res. 2006;12(19):5859\u201368. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-06-0935.","journal-title":"Clin Cancer Res"},{"issue":"23","key":"570_CR12","doi-asserted-by":"publisher","first-page":"6643","DOI":"10.1158\/0008-5472.Can-18-0933","volume":"78","author":"AR S\u00e1nchez-Paulete","year":"2018","unstructured":"S\u00e1nchez-Paulete AR, Teijeira \u00c1, Quetglas JI, Rodr\u00edguez-Ruiz ME, S\u00e1nchez-Arr\u00e1ez \u00c1, Labiano S, et al. Intratumoral immunotherapy with XCL1 and sFlt3L encoded in recombinant Semliki Forest virus-derived vectors fosters dendritic cell-mediated T-cell cross-priming. Cancer Res. 2018;78(23):6643\u201354. https:\/\/doi.org\/10.1158\/0008-5472.Can-18-0933.","journal-title":"Cancer Res"},{"issue":"9","key":"570_CR13","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1016\/j.ymthe.2018.06.001","volume":"26","author":"JM Santos","year":"2018","unstructured":"Santos JM, Cervera-Carrascon V, Havunen R, Zafar S, Siurala M, Sorsa S, et al. Adenovirus coding for interleukin-2 and tumor necrosis factor alpha replaces lymphodepleting chemotherapy in adoptive T cell therapy. Mol Ther. 2018;26(9):2243\u201354. https:\/\/doi.org\/10.1016\/j.ymthe.2018.06.001.","journal-title":"Mol Ther"},{"issue":"4-5","key":"570_CR14","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1023\/a:1025383913444","volume":"19","author":"CC Reed","year":"2002","unstructured":"Reed CC, Iozzo RV. The role of decorin in collagen fibrillogenesis and skin homeostasis. Glycoconj J. 2002;19(4\u20135):249\u201355. https:\/\/doi.org\/10.1023\/a:1025383913444.","journal-title":"Glycoconj J"},{"issue":"11","key":"570_CR15","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1002\/ijc.23930","volume":"123","author":"S Goldoni","year":"2008","unstructured":"Goldoni S, Iozzo RV. Tumor microenvironment: modulation by decorin and related molecules harboring leucine-rich tandem motifs. Int J Cancer. 2008;123(11):2473\u20139. https:\/\/doi.org\/10.1002\/ijc.23930.","journal-title":"Int J Cancer"},{"issue":"2","key":"570_CR16","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1089\/hum.2018.055","volume":"30","author":"H Zhao","year":"2019","unstructured":"Zhao H, Wang H, Kong F, Xu W, Wang T, Xiao F, et al. Oncolytic adenovirus rAd.DCN inhibits breast tumor growth and lung metastasis in an immune-competent orthotopic xenograft model. Hum Gene Ther. 2019;30(2):197\u2013210. https:\/\/doi.org\/10.1089\/hum.2018.055.","journal-title":"Hum Gene Ther"},{"issue":"6","key":"570_CR17","doi-asserted-by":"publisher","first-page":"194","DOI":"10.3390\/cancers10060194","volume":"10","author":"A Dahmani","year":"2018","unstructured":"Dahmani A, Delisle JS. TGF-\u03b2 in T Cell Biology: Implications for Cancer Immunotherapy. Cancers (Basel). 2018;10(6):194. https:\/\/doi.org\/10.3390\/cancers10060194.","journal-title":"Cancers (Basel)"},{"issue":"6","key":"570_CR18","doi-asserted-by":"publisher","first-page":"3569","DOI":"10.1007\/s11010-025-05224-z","volume":"480","author":"S Appunni","year":"2025","unstructured":"Appunni S, Saxena A, Ramamoorthy V, Zhang Y, Doke M, Nair SS, et al. Decorin: matrix-based pan-cancer tumor suppressor. Mol Cell Biochem. 2025;480(6):3569\u201391. https:\/\/doi.org\/10.1007\/s11010-025-05224-z.","journal-title":"Mol Cell Biochem"},{"issue":"8","key":"570_CR19","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1089\/hum.2017.033","volume":"28","author":"Z Liu","year":"2017","unstructured":"Liu Z, Yang Y, Zhang X, Wang H, Xu W, Wang H, et al. An Oncolytic Adenovirus Encoding Decorin and Granulocyte Macrophage Colony Stimulating Factor Inhibits Tumor Growth in a Colorectal Tumor Model by Targeting Pro-Tumorigenic Signals and via Immune Activation. Hum Gene Ther. 2017;28(8):667\u201380. https:\/\/doi.org\/10.1089\/hum.2017.033.","journal-title":"Hum Gene Ther"},{"issue":"1","key":"570_CR20","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/jlb.67.1.2","volume":"67","author":"C van Kooten","year":"2000","unstructured":"van Kooten C, Banchereau J. CD40-CD40 ligand. J Leukoc Biol. 2000;67(1):2\u201317. https:\/\/doi.org\/10.1002\/jlb.67.1.2.","journal-title":"J Leukoc Biol"},{"key":"570_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107709","volume":"219","author":"T Tang","year":"2021","unstructured":"Tang T, Cheng X, Truong B, Sun L, Yang X, Wang H. Molecular basis and therapeutic implications of CD40\/CD40L immune checkpoint. Pharmacol Ther. 2021;219:107709. https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107709.","journal-title":"Pharmacol Ther"},{"issue":"5","key":"570_CR22","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.4049\/jimmunol.1801630","volume":"203","author":"YK Takada","year":"2019","unstructured":"Takada YK, Yu J, Shimoda M, Takada Y. Integrin binding to the trimeric interface of CD40L plays a critical role in CD40\/CD40L signaling. J Immunol. 2019;203(5):1383\u201391. https:\/\/doi.org\/10.4049\/jimmunol.1801630.","journal-title":"J Immunol"},{"key":"570_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2024.101056","volume":"57","author":"PN Peters","year":"2024","unstructured":"Peters PN, Whitaker RS, Lim F, Russell S, Bloom EA, Pollara J, et al. Oncolytic adenovirus MEM-288 encoding membrane-stable CD40L and IFN\u03b2 induces an anti-tumor immune response in high grade serous ovarian cancer. Neoplasia. 2024;57:101056. https:\/\/doi.org\/10.1016\/j.neo.2024.101056.","journal-title":"Neoplasia"},{"issue":"8","key":"570_CR24","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/gt.2014.46","volume":"21","author":"YF Yang","year":"2014","unstructured":"Yang YF, Xue SY, Lu ZZ, Xiao FJ, Yin Y, Zhang QW, et al. Antitumor effects of oncolytic adenovirus armed with PSA-IZ-CD40L fusion gene against prostate cancer. Gene Ther. 2014;21(8):723\u201331. https:\/\/doi.org\/10.1038\/gt.2014.46.","journal-title":"Gene Ther"},{"issue":"1","key":"570_CR25","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s43556-024-00202-1","volume":"5","author":"Y Rong","year":"2024","unstructured":"Rong Y, Ning Y, Zhu J, Feng P, Zhu W, Zhao X, et al. Oncolytic adenovirus encoding decorin and CD40 ligand inhibits tumor growth and liver metastasis via immune activation in murine colorectal tumor model. Mol Biomed. 2024;5(1):39. https:\/\/doi.org\/10.1186\/s43556-024-00202-1.","journal-title":"Mol Biomed"},{"issue":"1","key":"570_CR26","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2020.1726168","volume":"9","author":"Y Luo","year":"2020","unstructured":"Luo Y, Lin C, Zou Y, Ju F, Ren W, Lin Y, et al. Tumor-targeting oncolytic virus elicits potent immunotherapeutic vaccine responses to tumor antigens. Oncoimmunology. 2020;9(1):1726168. https:\/\/doi.org\/10.1080\/2162402x.2020.1726168.","journal-title":"Oncoimmunology"},{"issue":"9","key":"570_CR27","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/nrd4663","volume":"14","author":"HL Kaufman","year":"2015","unstructured":"Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov. 2015;14(9):642\u201362. https:\/\/doi.org\/10.1038\/nrd4663.","journal-title":"Nat Rev Drug Discov"},{"issue":"15","key":"570_CR28","doi-asserted-by":"publisher","first-page":"5503","DOI":"10.1128\/mcb.20.15.5503-5515.2000","volume":"20","author":"AG Eliopoulos","year":"2000","unstructured":"Eliopoulos AG, Davies C, Knox PG, Gallagher NJ, Afford SC, Adams DH, et al. CD40 induces apoptosis in carcinoma cells through activation of cytotoxic ligands of the tumor necrosis factor superfamily. Mol Cell Biol. 2000;20(15):5503\u201315. https:\/\/doi.org\/10.1128\/mcb.20.15.5503-5515.2000.","journal-title":"Mol Cell Biol"},{"issue":"12","key":"570_CR29","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.1016\/j.immuni.2021.11.015","volume":"54","author":"DY Oh","year":"2021","unstructured":"Oh DY, Fong L. Cytotoxic CD4(+) T cells in cancer: expanding the immune effector toolbox. Immunity. 2021;54(12):2701\u201311. https:\/\/doi.org\/10.1016\/j.immuni.2021.11.015.","journal-title":"Immunity"},{"issue":"1","key":"570_CR30","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1186\/s12916-023-02901-y","volume":"21","author":"A Bahreyni","year":"2023","unstructured":"Bahreyni A, Liu H, Mohamud Y, Xue YC, Fan YM, Zhang YL, et al. A combination of genetically engineered oncolytic virus and melittin-CpG for cancer viro-chemo-immunotherapy. BMC Med. 2023;21(1):193. https:\/\/doi.org\/10.1186\/s12916-023-02901-y.","journal-title":"BMC Med"},{"issue":"1","key":"570_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.omton.2025.200936","volume":"33","author":"NTT Nh\u00e0n","year":"2025","unstructured":"Nh\u00e0n NTT, Shin SC, Filimon B, Yang Y, Hu Z, Brockstein B, et al. Oncolytic adenovirus inhibits TNBC tumor growth\/metastasis in mice by targeting TGF-\u03b2 and overexpressing GM-CSF. Mol Ther Oncolytics. 2025;33(1):200936. https:\/\/doi.org\/10.1016\/j.omton.2025.200936.","journal-title":"Mol Ther Oncolytics"},{"issue":"2","key":"570_CR32","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s44321-024-00187-y","volume":"17","author":"M Peter","year":"2025","unstructured":"Peter M, Mundt B, Menze A, Woller N, Volk V, Ernst AM, et al. Oncolytic viruses expressing MATEs facilitate target-independent T-cell activation in tumors. EMBO Mol Med. 2025;17(2):265\u2013300. https:\/\/doi.org\/10.1038\/s44321-024-00187-y.","journal-title":"EMBO Mol Med"},{"issue":"12","key":"570_CR33","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009716","volume":"12","author":"Y Cheng","year":"2024","unstructured":"Cheng Y, Zhao Y, Liu Y, Zhang Y, Xu D, Sun W, et al. Durable antitumor response via an oncolytic virus encoding decoy-resistant IL-18. J Immunother Cancer. 2024;12(12):e009716. https:\/\/doi.org\/10.1136\/jitc-2024-009716.","journal-title":"J Immunother Cancer"},{"issue":"3","key":"570_CR34","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/ncponc0101","volume":"2","author":"SA Rosenberg","year":"2005","unstructured":"Rosenberg SA. Cancer immunotherapy comes of age. Nat Clin Pract Oncol. 2005;2(3):115. https:\/\/doi.org\/10.1038\/ncponc0101.","journal-title":"Nat Clin Pract Oncol"},{"issue":"1","key":"570_CR35","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1046\/j.1365-2249.2002.01813.x","volume":"128","author":"JN Pettiford","year":"2002","unstructured":"Pettiford JN, Jason J, Nwanyanwu OC, Archibald LK, Kazembe PN, Dobbie H, et al. Age-related differences in cell-specific cytokine production by acutely ill Malawian patients. Clin Exp Immunol. 2002;128(1):110\u20137. https:\/\/doi.org\/10.1046\/j.1365-2249.2002.01813.x.","journal-title":"Clin Exp Immunol"},{"key":"570_CR36","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.crimmu.2021.08.002","volume":"2","author":"T Sarkar","year":"2021","unstructured":"Sarkar T, Dhar S, Sa G. Tumor-infiltrating T-regulatory cells adapt to altered metabolism to promote tumor-immune escape. Curr Res Immunol. 2021;2:132\u201341. https:\/\/doi.org\/10.1016\/j.crimmu.2021.08.002.","journal-title":"Curr Res Immunol"},{"key":"570_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1444533","volume":"15","author":"Y Yue","year":"2024","unstructured":"Yue Y, Ren Y, Lu C, Li P, Zhang G. Epigenetic regulation of human FOXP3+ Tregs: from homeostasis maintenance to pathogen defense. Front Immunol. 2024;15:1444533. https:\/\/doi.org\/10.3389\/fimmu.2024.1444533.","journal-title":"Front Immunol"},{"issue":"2","key":"570_CR38","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.trecan.2022.10.003","volume":"9","author":"R Ma","year":"2023","unstructured":"Ma R, Li Z, Chiocca EA, Caligiuri MA, Yu J. The emerging field of oncolytic virus-based cancer immunotherapy. Trends Cancer. 2023;9(2):122\u201339. https:\/\/doi.org\/10.1016\/j.trecan.2022.10.003.","journal-title":"Trends Cancer"},{"key":"570_CR39","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.canlet.2019.05.033","volume":"459","author":"Y Li","year":"2019","unstructured":"Li Y, Hong J, Jung BK, Oh E, Yun CO. Oncolytic Ad co-expressing decorin and Wnt decoy receptor overcomes chemoresistance of desmoplastic tumor through degradation of ECM and inhibition of EMT. Cancer Lett. 2019;459:15\u201329. https:\/\/doi.org\/10.1016\/j.canlet.2019.05.033.","journal-title":"Cancer Lett"},{"issue":"3","key":"570_CR40","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1007\/s10528-024-10835-0","volume":"63","author":"W Yu","year":"2025","unstructured":"Yu W, Yang M, Lv B, Yu Y, Zhu W. CD40L-Activated DC promotes Th17 differentiation and inhibits Th2 differentiation in sepsis-induced lung injury via cGAS-STING signaling. Biochem Genet. 2025;63(3):2455\u201369. https:\/\/doi.org\/10.1007\/s10528-024-10835-0.","journal-title":"Biochem Genet"},{"issue":"4","key":"570_CR41","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/s1470-2045(24)00079-2","volume":"25","author":"BL Musher","year":"2024","unstructured":"Musher BL, Rowinsky EK, Smaglo BG, Abidi W, Othman M, Patel K, et al. LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001): results from arm 1 of a non-randomised, single-centre, phase 1\/2 study. Lancet Oncol. 2024;25(4):488\u2013500. https:\/\/doi.org\/10.1016\/s1470-2045(24)00079-2.","journal-title":"Lancet Oncol"},{"issue":"1","key":"570_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/s43556-024-00212-z","volume":"5","author":"X Li","year":"2024","unstructured":"Li X, Zhang Y, Mao Z, Zhao H, Cao H, Wang J, et al. Decorin-armed oncolytic adenovirus promotes natural killers (NKs) activation and infiltration to enhance NK therapy in CRC model. Mol Biomed. 2024;5(1):48. https:\/\/doi.org\/10.1186\/s43556-024-00212-z.","journal-title":"Mol Biomed"},{"issue":"2","key":"570_CR43","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.cpt.2022.12.002","volume":"1","author":"H Ahmed","year":"2023","unstructured":"Ahmed H, Mahmud AR, Siddiquee MFR, Shahriar A, Biswas P, Shimul MEK, et al. Role of T cells in cancer immunotherapy: opportunities and challenges. Cancer Pathog Ther. 2023;1(2):116\u201326. https:\/\/doi.org\/10.1016\/j.cpt.2022.12.002.","journal-title":"Cancer Pathog Ther"},{"issue":"1","key":"570_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38679-z","volume":"14","author":"W Ban","year":"2023","unstructured":"Ban W, Sun M, Huang H, Huang W, Pan S, Liu P, et al. Engineered bacterial outer membrane vesicles encapsulating oncolytic adenoviruses enhance the efficacy of cancer virotherapy by augmenting tumor cell autophagy. Nat Commun. 2023;14(1):2933. https:\/\/doi.org\/10.1038\/s41467-023-38679-z.","journal-title":"Nat Commun"},{"issue":"1","key":"570_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-39683-z","volume":"14","author":"S Wang","year":"2023","unstructured":"Wang S, Yan W, Kong L, Zuo S, Wu J, Zhu C, et al. Oncolytic viruses engineered to enforce cholesterol efflux restore tumor-associated macrophage phagocytosis and anti-tumor immunity in glioblastoma. Nat Commun. 2023;14(1):4367. https:\/\/doi.org\/10.1038\/s41467-023-39683-z.","journal-title":"Nat Commun"},{"key":"570_CR46","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/j.fsi.2018.12.065","volume":"86","author":"YJ Ning","year":"2019","unstructured":"Ning YJ, Chen SY, Lu XJ, Lu JF, Chen J. Glucocorticoid receptor in ayu (Plecoglossus altivelis): genomic and non-genomic effects on monocytes\/macrophages function. Fish Shellfish Immunol. 2019;86:1151\u201361. https:\/\/doi.org\/10.1016\/j.fsi.2018.12.065.","journal-title":"Fish Shellfish Immunol"}],"container-title":["Molecular Biomedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-026-00570-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43556-026-00570-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-026-00570-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:01:33Z","timestamp":1791313293000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s43556-026-00570-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,5]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["570"],"URL":"https:\/\/doi.org\/10.1186\/s43556-026-00570-w","relation":{},"ISSN":["2662-8651"],"issn-type":[{"value":"2662-8651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,5]]},"assertion":[{"value":"25 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All animal experiments were conducted in accordance with institutional guidelines and were approved by the Institutional Animal Care and Use Committee (IACUC) of Guoke Ningbo Life Science and Health Industry Research Institute (Approval No.GK-2024-XM-1068).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Author Yuefeng Yang is an employee in Beijing Jingda Biotechnology Co. Ltd. The other authors have no conflicts of interest to declare.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"195"}}